Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElitePhysiqMD vs Wellorithm

ElitePhysiqMD
Graded #166

Higher grade

vs+19.099999999999994
Wellorithm
Graded #486

Lower grade

The verdict

ElitePhysiqMD takes it — 67.6/100 to 48.5/100.

ElitePhysiqMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElitePhysiqMD is a physician-led telehealth platform prescribing compounded semaglutide (from $145/mo) and tirzepatide (from $315/mo subscription) to patients in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueElitePhysiqMD +44
74
30
Dose & formulationWellorithm +28
64
92
Clinical oversightElitePhysiqMD +51
79
28
Labs & monitoringElitePhysiqMD +12
52
40
FulfillmentElitePhysiqMD +7
69
62
Contract termsElitePhysiqMD +10
55
45
ElitePhysiqMD · left barWellorithm · right bar

The numbers

MetricElitePhysiqMDWellorithm
WeighScore67.6/10048.5/100
GradeCC
Scorecard rank#166#486
Semaglutide$145/mo (starting dose, compounded)Pricing not published
Tirzepatide$315/mo (starting dose, compounded)Pricing not published
CoverageCoverage not published49 states (not Louisiana)
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
ElitePhysiqMD

Graded #166 · C

Strengths

  • Compounded semaglutide from $145/mo subscription with no video calls and cancel-anytime policy
  • LegitScript certified, HIPAA-compliant; prescriptions from board-certified physicians via 5-min online assessment
  • Medications from US-licensed 503A/503B compounding pharmacies, shipped discreetly in 5–7 business days
  • HSA/FSA eligible; accepts all 50 states with no insurance required
  • Peptide therapy also available: NAD+, sermorelin, CJC-1295/ipamorelin, GHK-Cu, and glutathione

Where it loses points

  • Required $49 telehealth visit is added to every order, increasing effective monthly cost above the headline price
  • No labs disclosed; medication plans don't appear to include bloodwork or baseline testing
  • No dietitian, coaching, or nutrition support mentioned; program is medication-only
  • Tirzepatide subscription price ($315/mo) is above the mid-range for compounded tirzepatide
  • Newer platform (founded late 2025); no Trustpilot rating or public patient reviews found
Wellorithm

Graded #486 · C

Strengths

  • Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
  • Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
  • Sermorelin offered alongside the GLP-1 line
  • 24/7 phone support on a published number

Where it loses points

  • No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
  • The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
  • The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
  • "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard